2005

Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial

Steven R. Simon
Sumit R. Majumdar
Lisa A. Prosser
Susanne Salem-Schatz
Cheryl Warner

See next page for additional authors

Follow this and additional works at: https://scholarworks.umass.edu/public_health_faculty_pubs
Part of the Biostatistics Commons, and the Epidemiology Commons

Recommended Citation
10.1016/j.ajmmed.2004.12.023
Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial

Steven R. Simon, Sumit R. Majumdar, Lisa A. Prosser, Susanne Salem-Schatz, Cheryl Warner, Ken Kleinman, Irina Miroshnik, Stephen B. Soumerai

PURPOSE: To compare group versus individual academic detailing to increase diuretic or β-blocker use in hypertension.

METHODS: We conducted a cluster-randomized controlled trial in a large health maintenance organization. Subjects (N=9820) were patients with newly treated hypertension in the year preceding the intervention (N=3692), the 9 months following the intervention (N=3556), and the second year following intervention (N=2572). We randomly allocated 3 practice sites to group detailing (N=227 prescribers), 3 to individual detailing (N=235 prescribers), and 3 to usual care (N=319 prescribers). Individual detailing entailed a physician-educator meeting individually with clinicians to address barriers to prescribing guideline-recommended medications. The group detailing intervention incorporated the same social marketing principles in small groups of clinicians.

RESULTS: In the first year following the intervention, the rates of diuretic or β-blocker use increased by 13.2% in the group detailing practices, 12.5% in the individual detailing practices, and 6.2% in the usual care practices. As compared with usual care practices, diuretic or β-blocker use was more likely in group detailing practices (adjusted odds ratio (OR), 1.40; 95% confidence interval (CI), 1.11 – 1.76) and individual detailing practices (adjusted OR, 1.30; 95% CI, 0.95 – 1.79). Neither intervention affected blood pressure control. Two years following this single-visit intervention, there was still a trend suggesting a persistent effect of individual (OR, 1.22; 95% CI, 0.92 – 1.62), but not group, detailing (OR, 1.06; 95% CI, 0.80 – 1.39), as compared with usual care.

CONCLUSION: Both group and individual academic detailing improved antihypertensive prescribing over and above usual care but may require reinforcement to sustain improvements.
Introduction

Despite the wide dissemination of evidence-based practice guidelines, the pharmacologic treatment of hypertension is suboptimal. Many patients with uncomplicated hypertension do not receive a diuretic or β-blocker, the guideline-recommended first-line medications that are relatively inexpensive and have proven superiority in preventing morbidity and mortality compared with newer classes of medication, with similar side effect profiles. In 1996, no more than 41% of patients with hypertension were taking a diuretic, β-blocker, or both drugs. Despite the morbidity and costs associated with hypertension and its complications, there have been few controlled studies of interventions to improve physicians’ prescribing behavior in hypertension.

Educational outreach, also called “academic detailing,” has been consistently demonstrated to be effective in improving physicians’ prescribing behaviors. Academic detailing involves the use of trained “detailers” (usually physicians or clinical pharmacists) conducting face-to-face visits with prescribers to encourage adoption of a desired behavior pattern. Academic detailing has rarely been studied in the setting of improving the treatment of hypertension. Although academic detailing was originally conceived and proven effective as a one-on-one educational intervention, several studies have incorporated academic detailing principles in small group sessions. In 1995 we conducted a quality improvement project using the principles of academic detailing to increase the use of diuretics and β-blockers among patients with hypertension. We recently analyzed the effects of this intervention, designed and carried out as a randomized controlled trial of group versus individual academic detailing, and mailed educational materials (“usual care”). Each experimental arm consisted of 3 practice groups (1 from each administrative division of the HMO). Practice administrators, clinicians, and patients were blinded with respect to study hypotheses. Blinding with respect to the experimental condition was not feasible. The institutional review boards of Harvard Medical School and of Harvard Pilgrim Health Care approved the study protocol.

Study patients

All patients with hypertension (either incident or prevalent) receiving primary care at one of the 9 study sites were eligible for analysis. We defined “incident” patients as those with newly diagnosed and treated hypertension within each time frame (baseline, initial follow up, long-term follow up). These patients were determined to have hypertension on the basis of having at least 2 outpatient encounters or 1 inpatient encounter with a hypertension diagnosis and evidence of a dispensed antihypertensive medication during the observation period. Thus, each analytic time period had a different cohort of incident patients. We associated a clinician with each patient by identifying the predominant prescriber of antihypertensive medications for that patient during the analytic time period of the patient’s incident hypertension.

In each time frame, we also identified patients with prevalent treated hypertension, defined as having at least 2 outpatient encounters or 1 inpatient encounter with a hypertension diagnosis and evidence of a dispensed antihypertensive medication during the 12-month period preceding the time frame of interest. A subset of prevalent patients in each time frame included patients who were considered to have incident treated hypertension in a preceding time frame.

Interventions

All clinicians providing primary care for adults at the 9 study sites were included. Before developing the academic detailing interventions, we carried out a focus group among 8 practicing physicians from the 3 HCHP administrative divisions. This 90-minute focus groups consisted of open-ended discussions to identify potential barriers practicing physicians perceived when treating hypertension in general and the advantages and disadvantages of first-line agents...
versus non-preferred agents. Three physician perceptions emerged as the core barriers to using diuretics or \( \beta \)-blockers:

1. “Large doses of old drugs, such as \( \beta \)-blockers and diuretics, fail to control blood pressure, while smaller doses of new drugs do.”
2. “Older drugs cause more side effects, like impotence, lethargy, and depression.”
3. “New drugs do lower blood pressure; therefore, long-term outcomes will be the same as older drugs.”

Physicians in the focus group session also expressed concern that patients would not understand a recommendation to return to older drugs when the physicians themselves may have previously discontinued the older drugs in favor of newer agents, such as ACE inhibitors or calcium-channel blockers. We developed counterarguments in response to each of these perceptions and concerns.

We selected 1 respected physician idea champion, or “peer leader,”29 from each HCHP administrative division to deliver the group and individual academic detailing sessions within that division. We conducted a full-day session to train the detailers, covering the principles of academic detailing, the clinical evidence and guidelines underlying the recommended prescribing practices, and role-playing. This session emphasized training the detailers to teach physicians strategies for talking with patients about starting or switching to the guideline-recommended agents.

**Usual care**

In April 1995, clinicians at all 9 practice sites received a mailing that contained printed material describing the current guidelines for prescribing antihypertensive medications and a laminated wallet card that summarized the guidelines.

**Individual academic detailing**

From July – September 1995, we conducted one-on-one educational outreach meetings among primary care physicians at each of the 3 practices randomized to this condition. The intervention consisted of a single visit (15-30 minutes) from the trained detailer, incorporating the core principles and methods of academic detailing, described in detail elsewhere.19 These principles included: 1) conducting surveys, interviews or focus group sessions to investigate baseline knowledge and motivation for current and proposed prescribing patterns; 2) establishing credibility through a respected organizational sponsor, referencing authoritative and unbiased information sources, and presenting both sides of controversial issues; 3) stimulating physician participation in two-way interaction; 4) using concise and visually appealing graphical educational materials, specifically addressing real and perceived barriers to change; and 5) repeating and positively reinforcing a small number of desired behaviors within each detailing encounter. More than 80% of the full-time primary care physicians at the individual detailing sites received the intervention.

**Group academic detailing**

During the intervention period, each of the 3 trained detailers delivered 45-minute small-group (7-8 clinicians in attendance) academic detailing sessions at sites randomized to this condition. Attendance records indicate that approximately 55% of the clinicians at the group detailing sites attended these group educational sessions, simply reflecting the fact that it was logistically more difficult to schedule group meetings rather than one-to-one visits. The sessions were designed using the principles of academic detailing described above.19 In addition, we employed supportive group processes, such as encouraging individual clinicians to share success stories in overcoming barriers to adhering to guideline recommendations and providing clinicians with an opportunity for mutual reinforcement of desired practice behaviors.

**Outcome measures**

We measured prescribing of antihypertensive medications using the pre-existing pharmacy dispensing (claims) databases of HCHP. The main outcome measure was change in guideline adherence (ie, the proportion of patients with incident hypertension receiving a diuretic or \( \beta \)-blocker). A patient was considered to have received a diuretic or \( \beta \)-blocker if he or she received at least one prescription for either drug during the specified time frame. As a secondary outcome measure, we determined whether each of the patients with prevalent hypertension previously treated with antihypertensive agents other than diuretics or \( \beta \)-blockers received one of the recommended agents in each time frame.

Blood pressure measurements were available for patients seen in the three practices within the one administrative division of the HMO that had an electronic medical record. Among patients with incident hypertension in these practices, we measured the last recorded blood pressure in the baseline year and in the initial post-intervention period.

We estimated the average person cost of antihypertensive medications for incident patients. We determined the number of patients in each experimental arm who received diuretics, \( \beta \)-blockers, calcium channel blockers and/or ACE inhibitors in the baseline year and in the initial post-intervention period. We multiplied the number of patients receiving each drug class by the annual cost (to the health plan) of the most commonly received agent and dosing strength within each class (ie, hydrochlorothiazide 25 mg for diuretics, atenolol 50 mg for \( \beta \)-blockers, nifedipine XL 60 mg for calcium channel blockers, and losinopril 20 mg for ACE inhibitors), assuming once-daily dosing. We summed all drug costs in each arm in each year and divided by the number of people in each group to obtain the annual antihypertensive drug costs per person.

We used administrative (claims) data to calculate rates of hospitalization across experimental arms in the pre-intervention and post-intervention years among patients with incident treated hypertension. In the administrative division
with an electronic medical record, we also measured outpa
tient visits. We determined the costs of the interventions
from administrative records and divided these costs by the
number of patients with incident hypertension in the base-
line year to obtain a conservative estimate of intervention
cost per patient.

Covariates

We used automated health plan data to ascertain the
following patient variables: age, sex, insurance type (HMO,
Medicare, Medicaid, fee-for-service), and continuous en-
rollment in the health plan. We determined presence or
absence of diabetes, based on one or more dispensed dia-
abetes medications or one inpatient or two outpatient visits
with diabetes codes during each patient’s first year of ob-
servation. We calculated a chronic disease score (CDS) for
each patient based on utilization of drugs for chronic disease
in the first year of the study.30,31 We determined the median
education level and median income of the census tract of
residence for each patient.

We ascertained prescriber variables (age, sex, years in
practice, degree [medical doctor, physician assistant, or
nurse practitioner]) by linking provider names from the
health plan claims data with public data bases.32,33

Statistical analysis

The unit of allocation and the unit of intervention were
the practice. The unit of analysis was the patient. To assess
baseline comparability, we compared intervention and usual
care patients with incident treated hypertension during the
pre-intervention period with regard to the use of antihyper-
tensive medications and other demographic and clinical
variables that may be associated with use of diuretics or
β-blockers.

We used logistic regression with generalized estimating
equations (GEE) to estimate the effect of the interventions
on prescribing of first-line agents and to control simulta-
neously for clustering at the level of the physician and for
differences among individual patients.28 In initial models,
we accounted only for clustering by physician. We also
evaluated models that adjusted simultaneously for patient
and prescriber characteristics. In these more detailed anal-
yses, point estimates and confidence intervals did not ma-
terially change; therefore we present only the cluster-ad-
justed estimates. Each model included all patients with
incident, treated hypertension in each study period. In ad-
dition, we used GEE to assess the effect of the interventions
on blood pressure, modeling the dichotomized outcome
(systolic blood pressure \( \leq 140 \) mm Hg versus \( > 140 \) mm
Hg).

All analyses used intention-to-treat principles, such that
clinicians practicing at a site were considered to have been
exposed to the intervention assigned to that site, regardless
of attendance at educational sessions. Similarly, all patients
were analyzed within the intervention arm to which their
predominant prescriber of antihypertensive medications was
assigned.

Results

Table 1 shows the baseline demographic and clinical
characteristics of patients with incident treated hyperten-
sion. The rates of use of diuretics or β-blockers across the
3 arms were almost identical, as were the age and sex
distributions and average chronic disease scores. Table 2
describes the characteristics of the primary care clinicians
within each experimental condition.

Intervention effects: incident patients

Figure 1 shows the absolute increases in the proportion
of newly diagnosed and treated hypertension patients re-
ceiving diuretics or β-blockers within each experimental
group in the first year and in the second year of follow up.
In the first year following the intervention, rates of use of
diuretics or β-blockers increased by 13.2% in the group
academic detailing practices, 12.5% in the individual detail-
ing practices, and 6.2% in the mailed practice guideline
(usual care) practices. These absolute increases correspond
to proportional increases of 22.3% (group detailing), 21.7%
(individual detailing), and 10.8% (usual care) as compared
with the baseline rates.

Relative to usual care practices, diuretic or β-blocker use
was more likely in group detailing practices (OR, 1.40; 95%
CI, 1.11 – 1.76) and individual detailing practices (OR,
1.30; 95% CI, 0.95 – 1.79), after controlling for physician-
level clustering. The effects of group and individual detail-
ing were of similar magnitude (OR for group versus indi-
vidual detailing, 1.10; 95% CI, 0.86 – 1.42).

In the second year following the intervention, the abso-
late increase in use of the guideline-recommended agents
over baseline was greater in the individual detailing prac-
tices (14.7%) than in the group detailing practices (11.3%)
or the usual care practices (10.1%) (Figure 1). During the
second year following the intervention, 72.3% of patients in
the individual detailing practices received diuretics or
β-blockers, as compared with 70.4% in the group detailing
practices and 67.7% in the mailed guideline practices. Al-
though not statistically significant, our data suggest that 2
years after the interventions, there was a trend suggestive of
a persistent effect of individual detailing (OR, 1.22; 95% CI,
0.92 – 1.62), but not group detailing (OR, 1.06; 95% CI,
0.80 – 1.39).

The intervention appeared to have no clinically mean-
ingful effect on blood pressure control. The mean systolic
blood pressure pre- and post-intervention in the 3 practice
sites in which these measurements were available are shown
in Figure 2. As compared with the patients in the mailed
guideline practice, patients in the individual detailing prac-
tice were slightly but not significantly less likely to have systolic blood pressure less than 140 mmHg in the first year following intervention (OR, 0.87; 95% CI, 0.55 – 1.39). Patients in the group detailing practice and those in the mailed guideline practice had similar probability of achieving this level of blood pressure control (OR, 0.98; 95% CI, 0.65 – 1.49).

**Intervention effects: prevalent patients**

There was no effect of either detailing intervention on switching patients with prevalent and treated hypertension to either diuretics or β-blockers. As compared with the mailed guideline practices, the odds ratio for switching to diuretics or β-blockers was 1.20 in the individual detailing practices (95% CI, 0.76 – 1.90) and 1.35 in the group detailing practices (95% CI, 0.89 – 2.06).

Considering incident patients who received a diuretic or β-blocker in the baseline year, 83% of patients in the individual detailing practices and 77% of patients in the group detailing practices remained on diuretics or β-blockers in the first year following the intervention, compared with 74% in the mailed guideline practices.

**Costs of antihypertensive medications, intervention costs, and utilization**

The estimated average per-person costs of antihypertensive medications in the baseline year were $288 in the mailed guideline practices, $277 in the individual detailing practices, and $269 in the group detailing practices. In the year following intervention, the per-person costs decreased to $219 in the mailed guideline practices, $198 in the individual detailing practices, and $220 in the group detailing practices. The per-patient reductions in medication costs were therefore $69 in the mailed guideline practices, $79 in the individual detailing practices, with a $1 per patient increase in the group detailing practices.

The overall intervention costs were $1000 for the mailed guideline intervention (approximately $1 per patient),

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Individual AD (N = 1066)</th>
<th>Group AD (N = 1007)</th>
<th>Mailed information (N = 1619)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>51.4</td>
<td>52.6</td>
<td>50.2</td>
</tr>
<tr>
<td>Female</td>
<td>48.6</td>
<td>47.4</td>
<td>49.9</td>
</tr>
<tr>
<td>Age, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 45 years</td>
<td>18.8</td>
<td>20.3</td>
<td>24.4</td>
</tr>
<tr>
<td>45–54 years</td>
<td>29.3</td>
<td>27.6</td>
<td>30.3</td>
</tr>
<tr>
<td>55–64 years</td>
<td>25.5</td>
<td>26.5</td>
<td>22.1</td>
</tr>
<tr>
<td>65–74 years</td>
<td>18.2</td>
<td>16.7</td>
<td>15.7</td>
</tr>
<tr>
<td>≥ 75 years</td>
<td>8.3</td>
<td>8.9</td>
<td>7.5</td>
</tr>
<tr>
<td>High school education, %*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median household income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25th percentile</td>
<td>$40,057</td>
<td>$33,734</td>
<td>$30,122</td>
</tr>
<tr>
<td>Median</td>
<td>$50,364</td>
<td>$40,888</td>
<td>$39,069</td>
</tr>
<tr>
<td>75th percentile</td>
<td>$65,674</td>
<td>$52,579</td>
<td>$47,552</td>
</tr>
<tr>
<td>Insurance type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMO</td>
<td>75.7</td>
<td>77.9</td>
<td>77.4</td>
</tr>
<tr>
<td>Medicare</td>
<td>20.0</td>
<td>18.2</td>
<td>17.4</td>
</tr>
<tr>
<td>Other†</td>
<td>4.3</td>
<td>4.0</td>
<td>5.2</td>
</tr>
<tr>
<td>Continuous health plan enrollment, %</td>
<td>76.5</td>
<td>78.2</td>
<td>73.3</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>9.4</td>
<td>10.7</td>
<td>12.7</td>
</tr>
<tr>
<td>Chronic disease score,‡ mean (sd)</td>
<td>893.2 (611)</td>
<td>890.1 (575.1)</td>
<td>899.4 (652.7)</td>
</tr>
<tr>
<td>Rates of antihypertensive medication use§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockers, %</td>
<td>37.2</td>
<td>34.9</td>
<td>33.9</td>
</tr>
<tr>
<td>Diuretics, %</td>
<td>28.7</td>
<td>32.3</td>
<td>32.2</td>
</tr>
<tr>
<td>β-blockers or diuretics, %</td>
<td>57.6</td>
<td>59.1</td>
<td>57.6</td>
</tr>
<tr>
<td>ACE inhibitors or ARB, %</td>
<td>46.8</td>
<td>42</td>
<td>46.2</td>
</tr>
<tr>
<td>Calcium-channel blockers, %</td>
<td>27.1</td>
<td>30.8</td>
<td>31.7</td>
</tr>
<tr>
<td>Other antihypertensive agents, %</td>
<td>6.4</td>
<td>6.6</td>
<td>6.1</td>
</tr>
</tbody>
</table>

Abbreviations: AD = academic detailing; HMO = health maintenance organization; ARB = angiotensin-receptor blocker; sd = standard deviation.
*Education level was missing for 111 patients who were under age 25 years.
†Includes Medicaid and indemnity insurance plans.
‡See description in text.
§Overall rates of antihypertensive medication use sum to greater than 100% because some patients were taking multiple medications.
$3500 ($3.50 per patient) for group detailing, and $5000 ($5 per patient) for individual detailing.

Table 3 shows the rates of hospitalization and office visits within the experimental conditions.

### Discussion

Few controlled studies have demonstrated improvements in the pharmacologic management of hypertension outside clinical trials.\(^{16,18}\) This study found that both individual and group academic detailing were effective in improving the initial pharmacologic treatment of hypertension. Both detailing interventions resulted in approximately 13% absolute increases (or 20% relative increases) in the use of guideline-recommended agents for patients with newly treated hypertension, as compared with usual care. Our data suggest that the increased use of guideline-adherent therapies did not affect blood pressure control.

By the second year following the single-visit interventions, the effects of both group detailing and individual detailing had decayed. There was a nonsignificant trend toward a persistent effect in the individual detailing arm but not in the group detailing arm. To date, few studies have demonstrated the persistence of the effect of academic detailing beyond the first 6-12 months following intervention.\(^{34}\) It is likely that a reinforcement session of some type would be necessary to maintain changes in behavior and, possibly, to engage physicians not captured in the initial session.

Neither detailing intervention resulted in any effect on switching patients to diuretics or \(\beta\)-blockers. Engaging physicians to switch patients’ therapies likely requires more intensive intervention strategies than a single educational outreach visit.

Both group and individual academic detailing have been shown in prior studies to produce, on average, 15-30% relative increases over baseline in the desired clinical behavior.\(^{21,23,27}\) We observed effects of similar magnitude in the present study.

Because diabetes may be treated with ACE inhibitors as the first-line agent, we controlled for this condition in the main analyses and this is thus unlikely to confound our observed effects.

A full economic analysis of the costs and cost-savings related to the academic detailing interventions is beyond the scope of this study. Nevertheless, our observations indicate that the group detailing intervention ($3500) cost less than the individual detailing intervention ($5000) and that these intervention costs were of the same magnitude as the medication cost savings.

This study has several limitations. First, it was conducted in a single managed care organization, which limits the generalizability of the findings. However, this setting was a mixed-model HMO, including both staff- and group-model divisions. Furthermore, the large majority of health care in
Second, baseline adherence rates (58-59%) were substantially higher than national figures from the same time period. We did not target the intervention to clinicians whose prescribing patterns indicated greater potential for improvement, one of the original core principles of academic detailing. Such targeting would likely have increased the observed effects of the academic detailing interventions.

Finally, although some may consider the age of our data to be the most important limitation of this study, the core guideline recommendations for diuretics and β-blockers as first-line agents in hypertension have remained unchanged.

Despite more than 25 years of widely circulated guidelines for care of patients with high blood pressure, evidence-based treatment of hypertension continues to elude a large segment of clinical practice in the United States. We found that both individual and group academic detailing can increase the use of guideline-based treatments in hypertension. Further study is needed to understand the economic ramifications of expanding this kind of intervention to improve the care of hypertension and other chronic diseases.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Rates of hospitalization and outpatient visits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Individual detailing</td>
</tr>
<tr>
<td>Hospitalizations per patient, mean (sd)</td>
<td></td>
</tr>
<tr>
<td>Baseline (N = 3692)</td>
<td>0.26 (0.79)</td>
</tr>
<tr>
<td>Follow-up Year 1 (N = 2142)</td>
<td>0.18 (0.63)</td>
</tr>
<tr>
<td>Outpatient visits per patient, mean (sd)</td>
<td></td>
</tr>
<tr>
<td>Baseline (N = 1534)</td>
<td>9.36 (7.26)</td>
</tr>
<tr>
<td>Follow-up Year 1 (N = 811)</td>
<td>10.03 (8.30)</td>
</tr>
</tbody>
</table>

Abbreviation: sd = standard deviation.
References